Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD® Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States

摘要

IntroductionVascular targeted photodynamic therapy (VTP) with WST11 (TOOKAD^® Soluble; STEBA Biotech, Luxembourg) is a form of tissue ablation that may be used therapeutically for localized prostate cancer (PCa). To study dosing parameters and associated treatment effects we undertook a prospective multicenter phase I/II trial of WST11 VTP for treatment of PCa